Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (71-80 of 201) with videos related to

Pageof 21
Sort By:
Gynecology & Obstetrics (Sunnyvale, Calif.)|December 20, 2021
The Overtreatment and Cost Effectiveness of Primary <i>versus</i> Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)Peter G Rose, Meng Yao, Laura M Chambers, et al.
Gynecologic Oncology Reports|December 6, 2023
Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case seriesPeter G Rose, Myra Feldman, Iwona Podzielinski, et al.
Gynecologic Oncology|June 6, 2020
Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancerLaura M Chambers, Adam Pendlebury, Peter G Rose, et al.
American Journal of Obstetrics and Gynecology|December 19, 2008
Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinomaBehiye P C Goksedef, Charles Kunos, Jerome L Belinson, et al.
Investigational New Drugs|May 4, 2004
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology GroupRussell J Schilder, John A Blessing, Michael L Pearl, et al.
Gynecologic Oncology|August 23, 2005
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinomaPeter G Rose, Mary Smrekar, Pamela Haba, et al.
Journal of Gynecologic Oncology|October 15, 2015
The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy aloneHaider Mahdi, Benjamin Nutter, Fadi Abdul-Karim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 27, 2014
Racial disparity in 30-day morbidity and mortality after surgery for ovarian cancerHaider Mahdi, Amelia Jernigan, David Lockhart, et al.
Gynecologic Oncology|March 23, 2011
Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group studyPeter G Rose, Shamshad Ali, Charles W Whitney, et al.
Gynecologic Oncology|April 2, 2002
A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group studyPeter G Rose, Michael Rodriguez, Joan Walker, et al.
Pageof 21

Showing results (71-80 of 201) with videos related to

Sort By:
Pageof 21
Gynecology & Obstetrics (Sunnyvale, Calif.)|December 20, 2021
The Overtreatment and Cost Effectiveness of Primary <i>versus</i> Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC)Peter G Rose, Meng Yao, Laura M Chambers, et al.
Gynecologic Oncology Reports|December 6, 2023
Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case seriesPeter G Rose, Myra Feldman, Iwona Podzielinski, et al.
Gynecologic Oncology|June 6, 2020
Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancerLaura M Chambers, Adam Pendlebury, Peter G Rose, et al.
American Journal of Obstetrics and Gynecology|December 19, 2008
Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinomaBehiye P C Goksedef, Charles Kunos, Jerome L Belinson, et al.
Investigational New Drugs|May 4, 2004
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology GroupRussell J Schilder, John A Blessing, Michael L Pearl, et al.
Gynecologic Oncology|August 23, 2005
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinomaPeter G Rose, Mary Smrekar, Pamela Haba, et al.
Journal of Gynecologic Oncology|October 15, 2015
The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy aloneHaider Mahdi, Benjamin Nutter, Fadi Abdul-Karim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 27, 2014
Racial disparity in 30-day morbidity and mortality after surgery for ovarian cancerHaider Mahdi, Amelia Jernigan, David Lockhart, et al.
Gynecologic Oncology|March 23, 2011
Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group studyPeter G Rose, Shamshad Ali, Charles W Whitney, et al.
Gynecologic Oncology|April 2, 2002
A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group studyPeter G Rose, Michael Rodriguez, Joan Walker, et al.
Pageof 21